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Four cases of infection with serogroup X meningococci 
(MenX) (1 in 2015 and 3 in 2016) occurred in migrants li-
ving in refugee camps or reception centers in Italy. All MenX 
isolates were identified as clonal complex 181. Our report 
suggests that serogroup X represents an emerging health 
threat for persons arriving from African countries. 
Outbreaks of Neisseria meningitidis serogroup X menin-gococcal (MenX) infections in the African meningitis 
belt caused by isolates of clonal complex (CC) 181, includ-
ing an outbreak in 2006 in Niger and one during 2007–2010 
in Togo and Burkina Faso (1,2), were characterized by high 
rates of illness and death. Sporadic infections caused by 
MenX of different CCs have also been identified in Italy 
(3), Spain (4), and China (5).
Moreover, serogroup X invasive isolates from other 
European countries reported and available in the PubMLST 
database (http://pubmlst.org/neisseria/) showed high het-
erogeneity among themselves and with the MenX isolates 
of the African meningitis belt. Because of the lack of a spe-
cific herd immunity against this serogroup in Europe, non-
African MenX isolates may be associated with increased 
host susceptibility (4).
Recently, the Italian Reference Laboratory for Invasive 
Meningococcal Disease (IMD) surveillance of the Istituto 
Superiore di Sanità, Rome, Italy, received samples from 4 
unlinked case-patients with serogroup X IMD that occurred 
among migrants living in refugee camps or reception cen-
ters. The first case was reported in 2015 in a 15-year-old 
girl from Eritrea (ID2683) who had arrived in a refugee 
camp in Lombardy, Italy, 3 days before onset of disease, 
which manifested as septicemia. The other 3 cases were 
reported in 2016, two in Lombardy (in a 20-year-old man 
from Mali, ID2820, and a 31-year-old man from Niger, 
ID2849) and another in a Tuscany camp (in a 24-year-man 
from Bangladesh, ID2805). These cases were characterized 
by meningitis with fever >40°C and loss of consciousness. 
All patients were treated with ceftriaxone and survived. 
Chemoprophylaxis with rifampin or ciprofloxacin was ad-
ministered to all persons directly exposed to the index case-
patients. The man from Bangladesh lived in a camp with 
other Africa refugees for several months before disease on-
set, but symptoms developed in the other 3 patients shortly 
after their arrival in Italy.
Sample ID2849 was culture negative and characterized 
only by finetype (online Technical Appendix Table, http://
wwwnc.cdc.gov/EID/article/23/5/16-1713-Techapp1.pdf).
We performed whole-genome sequencing and assembly on 
the other 3 isolates by using an Illumina MiSeq sequencer 
(Illumina, San Diego, CA, USA) (6). Genomes are avail-
able through the PubMLST database, which runs on the 
Bacterial Isolate Genome Sequence Database platform (7). 
The 4 isolates were further analyzed by core genome 
multilocus sequence typing (cgMLST) and compared with 
all serogroup X genomes (n = 36) in the PubMLST data-
base (as of December 28, 2016) (7). The isolates bifurcated 
into 2 main groups, of which CC181 genomes clustered in a 
single branch (Figure, panel A). Of 18 CC181 genomes, 17 
were resolved in 3 main groups (Figure, panel B), according 
to 3 main finetypes: group 1, finetype X:P1.5–1,10–1:F1–
31:ST181 (CC181); group 2, finetype X:P1.5–1,10–1:F4–
23:ST5789 (CC181); group 3, finetype X:P1.5–1,10–1:F4–
23:ST181 (CC181). One CC181 genome (ID LNP13407) 
was positioned in a branch far from the 3 main groups. 
Two of the strains identified in Italy in 2016 (ID2805 and 
ID2820) clustered in group 1 with 7 MenX strains isolated 
from 2005 and 2016 in Niger, Burkina Faso, Benin, and the 
United Kingdom (mean distance 3 loci). Notably, the UK 
MenX CC181 strain (ID M16_240550) clustered close to 
the Italy strains (mean distance 24 loci). The strain diag-
nosed in Italy in 2015 (ID2683) clustered in group 2 with 
3 strains isolated in 2006 in Niger (mean distance 36 loci). 
Group 2 was strictly related to group 3, comprising 4 me-
ningococci strains isolated during 1996–2002 in Niger. 
As described by Agnememel et al. (8), MenX iso-
lates from Africa were genetically related: they belonged 
to CC181and formed a single main lineage. Our genome 
analyses confirmed the presence of MenX strains with sim-
ilar characteristics to those already described.  In particular, 
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these isolates harbored lpt3 allele 45, previously described 
as a high virulence marker in the mouse model (8).
The analysis of meningococcal serogroup B vac-
cines antigens (PorA, fHbp, NadA and NHBA) identified 
the variants PorA VR2 10–1, fHbp-1.74 (Pfizer family 
B, variant B49), and NHBA-359 for samples ID2805, 
ID2820, and ID2849 and fHbp-1.391 (Pfizer family B) 
and NHBA-358 for isolate ID2683. fHbp and NHBA 
variant patterns had been associated with MenX CC181 
isolated in Africa. NadA was absent in all analyzed MenX 
CC181 meningococci.
The probability of a migrant developing an infectious 
disease, such as IMD, after arriving in the country of desti-
nation may depend on a series of factors, such as the preva-
lence and incidence of the infectious diseases in the coun-
try of origin, the specific characteristics of the infectious 
diseases (incubation period), the number of contacts that 
the migrant had during the journey, and the duration of the 
journey. These factors should be taken into account when 
assessing the risk of developing specific infectious diseas-
es, such as IMD. Our report suggests that MenX represents 
an emerging health threat for persons arriving in Italy from 
Africa. Early diagnosis, treatment, and prophylaxis should 
be ensured to protect vulnerable populations, including mi-
grants, refugees, and the host community.
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Figure. Analysis of Neisseria meningitidis serotype X (MenX) isolates from 3 refugees in Italy and comparison isolates from the 
Neisseria PubMLST database (http://pubmlst.org/neisseria/), as of December 28, 2016). A) Neighbor-net phylogenetic network 
based on a comparison of core genome loci of all MenX genomes (n = 36) available in PubMLST database. For each strain, the 
available designation by clonal complex (CC) or sequence type (ST) is indicated. B) Neighbor-net phylogenetic network  
showing 3 isolates from Italy (stars) compared with core genome loci (MenX CC181 genomes (n = 18) available in the Neisseria  
PubMLST database. Source locations for comparison isolates are indicated. Scale bars indicate number of differences among the 
loci compared. 
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An investigation in Panama found that Punta Toro virus 
species complex (PTVs) may contribute to febrile illnesses 
with symptoms mirroring those of dengue fever. However, 
further studies are needed to determine if PTV infection 
causes only a mild disease or if it can have more serious 
manifestations in some patients.
Acute febrile illness in the New World tropics has a broad differential diagnosis largely dependent on lo-
cale and seasonal outbreaks. In Central America, most fe-
brile illnesses have historically been attributed to dengue 
or malaria. However, recent evidence from Panama sug-
gests varied differential diagnoses, including hantavirus, 
chikungunya virus, and Zika virus infection (1,2). In 2009, 
a dengue outbreak was reported in Panama City, Panama. 
The Gorgas Memorial Institute in Panama City tested den-
gue-negative samples from this outbreak for alphaviruses, 
flaviviruses, and phleboviruses and detected Punta Toro vi-
rus species complex (PTVs) in some samples. PTV (genus 
Phlebovirus, family Bunyaviridae), a member of the sand 
fly fever group, was initially described in humans in 1966 
after being isolated from a soldier in Panama who had fever, 
headache, myalgia, and leukopenia (3). The phylogenetics 
of PTV have been thoroughly characterized (4–6), but our 
search of the literature did not reveal reports of other PTV 
cases in humans.
The signs and symptoms of sand fly–associated 
phlebovirus infection vary, but most infections cause a 
mild febrile illness characterized by retroorbital headache, 
weakness, back pain, and leukopenia. However, infection 
with 2 other phleboviruses, mosquitoborne Rift Valley fe-
ver virus and tick-associated severe fever with thrombo-
cytopenia syndrome virus, causes severe disease. Little is 
known regarding the signs, symptoms, and clinical course 
of PTV infection in humans.
During the 2009 investigation, the Gorgas Memorial 
Institute analyzed 4,852 samples from persons in Panama 
with suspected acute dengue; 1,667 (34.4%) of the sam-
ples were dengue-negative. We further analyzed 201 of 
these samples for phlebovirus (online Technical Appendix 
Table 1, https://wwwnc.cdc.gov/EID/article/23/5/16-1925-
Techapp1.pdf). In brief, we extracted viral RNA from the 
samples and evaluated it by using Phlebovirus genus–spe-
cific reverse transcription PCR (RT-PCR) based on the 
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